Up-to-date news about Intravacc
Stay informed about the latest developments in our mission to pioneer transformative vaccines with up-to-date corporate communications. Get the latest news on our development and business milestones, as well as industry insights, partnership announcements, and corporate reports.
Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
Read our latest publication about our Outer Membrane Vesicle (OMV) platform: an insightful interview with our VP of R&D, Dinja Oosterhoff, PhD
We interviewed Paul, our new Director QA/QC & EHS to learn about his career and his passion for quality.
Intravacc secures $633K funding from CARB-X to develop a vaccine against Neisseria gonorrhoeae.
On the third of May last year the Ministry of Health, Welfare, and Sport (VWS) announced the sale of Intravacc B.V. and on December 28, 2023 VWS…
We are thrilled to announce the launch of our new website!
Interview with Intravacc’s CEO dr. Jan Groen “Some milestones are measured by reliability”
In vitro alternative assay to the replace rabbit pyrogen test for vaccines.
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
